Ewing sarcoma (EwS) is an aggressive cancer caused by chromosomal translocations generating fusions of the EWSR1 gene with ETS transcription factors (in 85% FLI1). EWSR1-FLI1 induces gene expression via binding to enhancer-like GGAA-microsatellites, whose activity increases with the number of consecutive GGAA-repeats.
INTRODUCTION
Ewing sarcoma (EwS) is a malignant tumor of bone and soft tissue predominantly affecting children and adolescents 1 . Since specific treatment options do not exist, current therapy concepts comprise local surgery combined with conventional poly-chemotherapy and irradiation 1 . Despite such intense conventional therapy, prognosis of patients with metastatic disease still remains poor 2 .
Thus, specific and, in particular, less toxic treatment options are urgently required.
EwS is characterized by gene fusions involving the EWSR1 gene on chromosome 22 (chr22) and various members of the ETS family of transcription factors -most commonly FLI1 on chr11 (85% of cases) 1 . EWSR1-FLI1 can arise either through balanced chromosomal translocations or through complex genomic breakage/fusion events 3, 4 . Notably, EWSR1-FLI1 encodes an aberrant chimeric transcription factor, which binds DNA at ETS-like GGAA-motifs and furthermore at GGAAmicrosatellites consisting of multiple sequential GGAA-motifs 5 . While EWSR1-FLI1 binding at single ETS-like motifs in gene promoters either activates or represses gene transcription, EWSR1-FLI1 binding at GGAA-microsatellites creates de novo enhancers, whose activity correlates positively with the number of consecutive GGAA-repeats 1, 6, 7 .
Although EwS is genetically well characterized, its precise cell of origin remains controversial.
Transcriptome profiling and functional studies suggested that EwS may arise from mesoderm-or neural crest-derived mesenchymal stem cells 8, 9 . Due to this histogenic uncertainty, there is currently no bona fide genetically engineered animal model available for EwS, which hampers the development of new therapeutic strategies 1, 10 . In addition, recent sequencing efforts revealed, EWSR1-ETS translocations being virtually the only highly recurrent somatic mutation in EwS 11, 12 .
Like many other ligand-independent inducible transcription factor oncoproteins, also EWSR1-FLI1 proved to be notoriously difficult to target 1, 13 . However, the EWSR1-FLI1-induced transcriptomic signature may harbor specific changes that could be exploited therapeutically.
To explore such EWSR1-FLI1 surrogate targets, we focused in this study on the putative EWSR1-FLI1 target gene CALCB (calcitonin related polypeptide β; alias CGRP2, calcitonin gene-related peptide 2), which encodes a neuropeptide that was already described in 1987 to be highly expressed in a EwS cell line 14, 15 . Nevertheless, its functional effects in EwS have remained unexplored until now.
The CALCB gene is located next to its homolog CALCA (calcitonin related polypeptide α) on chr11p15.2 and encodes a secretory neuropeptide composed of 37 amino acids 16, 17 . CALCB is predominantly expressed in the central nervous system and causes potent vasodilatation 18, 19 .
Signaling of both, CALCA and CALCB, is mediated through G protein coupled receptor complexes present on the cell surface. There is a variety of different receptors, formed by heterodimerization, which recognize both peptides. Most importantly they are recognized by the so called CGRP-receptor, which is formed by the calcitonin receptor-like receptor (CLR, encoded by the CALCRL gene) and RAMP1 (receptor activity-modifying protein 1). RAMP1 makes the receptor-complex specific for the binding of CALCA and CALCB 20, 21 . Receptor-ligand interaction leads to G protein mediated increase in intracellular cAMP-levels 22 . Apart from the above described CGRP-receptor, CALCB also binds to a receptor complex consisting of RAMP1 and the calcitonin receptor (CTR, encoded by the CALCR gene), which is called AMY1-(amylin subtype 1) receptor. However, this receptor is not specific for CALCA and CALCB but is also activated by binding of islet amyloid polypeptide (IAPP). Since the biological role of AMY1 is not fully understood, and given that both CALCR and IAPP are not or only barely expressed in EwS ( Supplementary Fig. S1 ), we focused in this study on CALCB and the first CGRP-receptor containing CLR and RAMP1 21 .
Here, we show that CALCB is an EWSR1-FLI1 target gene highly overexpressed in EwS as compared to normal tissues and other childhood malignancies, and that its high expression is likely mediated through EWSR1-FLI1 binding to an enhancer-like GGAA-microsatellite. Proteomic and functional analyses revealed that CALCB, but not CALCA, is secreted by EwS cells and that suppression of either CALCB or its receptor RAMP1 significantly reduced proliferation and clonogenic/spheroidal growth of EwS cells in vitro, as well as tumor growth in vivo, which can be mimicked in vitro by application of the small molecule CGRP-receptor inhibitors MK-3207 and BIBN-4096 (Olcegepant).
MATERIALS & METHODS

Analysis of microarray data
The microarray datasets for cancer and normal tissues were downloaded from public repositories and processed as described previously 23 . Data were generated on Affymetrix HG-U133Plus2.0 microarrays and normalized simultaneously by Robust Multi-chip Average (RMA) using brainarray chip description files (CDF; ENTREZg, v21) yielding one optimized probe-set per gene 24, 25 . Accession codes of used datasets are given in Supplementary Table 1 .
Cell culture and provenience of cell lines
A673, HEK-293T, and SK-PN-DW cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA; CRL-1598, CRL-1573, and CRL-2139, respectively).
RDES, SK-ES1, SK-N-MC, and MHH-ES1 cells were provided by the German collection of
Microorganism and Cell lines (DSMZ, Braunschweig, Germany). TC-71 cells were kindly provided by the Children's Oncology Group (COG, Monrovia, CA, USA) and ES7, EW-1, EW-3, EW-7, EW-16, EW-18, EW-22, EW-24, LAP35, MIC, ORS, POE, SKNPLI, and STA-ET1 cells were provided by O. Delattre (Institute Curie, Paris, France). SB-KMS-KS1 was established in the Department of Pediatrics at the TU Munich (Munich, Germany) and described previously 26 . A673/TR/shEF1 cells, which contain a doxycycline (dox)-inducible shRNA against EWSR1-FLI1, were kindly provided by J. Alonso (Madrid, Spain) 27 . All cell lines were grown at 37°C and 5% CO2 in a humidified atmosphere. RPMI 1640 medium with stable glutamine (Biochrom, Berlin, Germany), 10% tetracycline-free FCS (Biochrom), 100 U/ml penicillin (Biochrom), and 100 µg/ml streptomycin (Biochrom) was used as standard medium to grow the cells. For cell lines, which tend to grow in suspension, TPP cell culture flasks (Faust, Klettgau, Germany) were coated with 1:40 PBS (Biochrom) diluted collagen solution (Sigma-Aldrich/Merck Millipore, Darmstadt, Germany) in order to keep them attached to the flasks. Cells were routinely checked for mycoplasma infection by nested PCR. Cell line purity was confirmed by STR profiling.
RNA extraction, reverse transcription, and quantitative real-time PCR (qRT-PCR)
RNA for analysis of gene expression with qRT-PCR from cell lysates and frozen tumor tissue was extracted using the NucleoSpin RNA Kit (Macherey-Nagel, Düren, Germany). Subsequent reverse transcription was performed with the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA) utilizing 1 µg RNA per reaction and following manufacturers' protocol of both kits. qRT-PCRs were performed using SYBR green (Applied Biosystems, Waltham, MA, USA) with a total volume of 15 µl. cDNA was diluted 1:10 and concentration of primers was 0.5 µM. Oligonucleotides were purchased from MWG Eurofins Genomics (Ebersberg, Germany). Expression levels were determined with the CFX Connect Real time PCR Cycler (Bio-Rad Laboratories, Hercules, CA, USA) in a two-step protocol: initial enzyme activation and denaturation at 95°C for 2 min, denaturation at 95°C for 10 sec, and annealing and extension at 60°C for 20 sec (repeating the last two steps 49 times), followed by a melting curve starting at 55°C and increasing by 0.5°C every 10 sec until a temperature of 95°C was reached. Expression levels were calculated according to the 2 -ΔΔCT method 28 . RPLP0 served as housekeeping gene. Primer sequences were as follows:
Quantification of CALCB gene expression levels in EwS cell lines
Different EwS cell lines were cultured under standard conditions. After a minimum of 48 h of culture, cells were harvested at a confluency of approximately 80%, and RNA extraction was carried out. CALCB expression was determined using qRT-PCR as described. CALCB expression levels were calculated relative to that of the A673 EwS cell line.
Quantification of EWSR1-FLI1-dependent CALCB gene expression in vivo
For analysis of in vivo CALCB expression depending on EWSR1-FLI1, 5 ´ 10 6 A673/TR/shEF1
EwS cells, which harbor a dox-inducible shRNA against EWSR1-FLI1, were injected subcutaneously in the flanks of immunocompromised NSG (Nod/scid/gamma) mice. When tumors reached an average volume of 180 mm 3 , mice were randomized and either received 2 mg/ml dox (Beladox, bela-pharm, Vechta, Germany) and 5% sucrose (Sigma-Aldrich/Merck Millipore) in the drinking water (dox +) or only 5% sucrose (dox -). Mice were sacrificed 96 h after beginning of For the luciferase reporter assay, 2 × 10 5 A673/TR/shEF1 EwS cells, harboring a dox-inducible shRNA against EWSR1-FLI1, were plated out in a well of a 6-well plate (TPP, Faust) in 1.8 ml of growth medium and transfected with the microsatellite-containing pGL3-luc vector and Renilla pGL3-Rluc vector (ratio, 100:1) using Lipofectamine LTX with Plus Reagent (Thermo Fisher Scientific). Transfection media was replaced by media with/without dox (1 µg/ml; VWR/Merck, Radnor, PA, USA) 4 h after transfection. After 72 h, the cells were lysed and assayed with a dual luciferase assay system (Berthold Technologies, Bad Wildbad, Germany). Firefly luciferase activity was normalized to Renilla luciferase activity.
Dual luciferase reporter assays
Gene set enrichment analysis (GSEA)
To identify gene signatures and biological processes associated with CALCB in normalized gene expression data from 166 primary EwS 32 , GSEA was performed on lists of genes ranked by their correlation coefficient with CALCB (MSigDB, c2.cpg.v6.2). GSEA was carried out with 1,000 permutations in default settings 33 .
Generation of cell lines with dox-inducible shRNAs
For generation of dox-inducible EwS cell lines (here in A673 and RDES), either a non-targeting negative control shRNA (MWG Eurofins Genomics) or specific shRNAs targeting CALCB or RAMP1 (MWG Eurofins Genomics) were cloned in the pLKO-Tet-on-all-in-one system (Addgene plasmid # 21915, Cambridge, MA, USA) as described previously 34 . Lentivirus production was performed in HEK-293T cells. A673 and RDES EwS cells were infected with the respective lentiviruses and selected with 1.5 µg/ml puromycin (Invivogen, Toulouse, France). Single cell cloning was performed, and knockdown efficacy of individual clones was assessed by qRT-PCR 48 h after addition of dox (1 µg/ml; VWR/Merck). The shRNA target sequences were as follows:
Proliferation assays
1-5 ´ 10 5 cells were seeded in 6-well plates (TPP, Faust) in 1.5 ml of standard growth medium. the medium was exchanged and after another 24 h a second transfection was performed. Cell counts were determined by using standardized hemocytometers (C-chips, Biochrom) and Trypan-blue (Sigma-Aldrich/Merck Millipore) exclusion 72 h after seeding in the short-term proliferation assay and 6-9 days after seeding in the long-term proliferation assay.
Colony-forming assay
A673 and RDES EwS cells harboring a dox-inducible shRNA construct against CALCB or RAMP1 or RDES wildtype cells were seeded at concentrations of 100-1,000 cells per well of 12-well plates and grown in standard culture medium for 12-14 days. Cells were treated with/without 1 µg/ml dox (VWR/Merck) and RDES wildtype cells were serially transfected with a non-targeting siRNA or siRNAs against CALCB (as described above). Colonies were stained with crystal violet (Sigma-Aldrich/Merck Millipore) and the number of colonies was quantified using ImageJ.
Sphere-formation assay
For analysis of 3D sphere formation, A673 and RDES EwS cells harboring a dox-inducible shRNA construct against CALCB or RAMP1 were seeded at a density of 1,000 cells/well of ultra-low attachment 96-well plates (Corning, NY, USA) in 80 µl standard cell culture medium with/without dox (1 µg/ml; VWR/Merck). The culture medium was refreshed by adding 10 µl medium with/without dox on top every second day. Spheroidal growth was monitored for 14 days.
Thereafter, phase-contrast imaging and morphological analyses of spheres were carried out with an inverted Zeiss Axiovert 25 microscope (Jena, Germany) equipped with a Zeiss Axiocam 105 color camera (Aptina CMOS Color Sensor, square pixels of 2.2 µm side length, 2,560 × 1,920 pixel resolution). Sphere numbers and diameters were analyzed with ImageJ.
Analysis of tumor growth in vivo
2.5 ´ 10 6 A673 EwS cells harboring a dox-inducible shRNA construct against CALCB or RAMP1 or a non-targeting control shRNA (shControl) were injected subcutaneously in NSG mice. After 10-14 days, when tumors were first palpable, mice were randomized and thereafter received either water (dox +) or 5% sucrose in sterile water alone (dox -). Tumor growth was monitored with a caliper every other day and mice were sacrificed by cervical dislocation when the tumors exceeded an average diameter of 15 mm (prior start of the experiment defined as "event"). Experiments were approved by local authorities and conducted in accordance with the recommendations of the European Community (86/609/EEC) and UKCCCR (guidelines for the welfare and use of animals in cancer research). 
Small-molecule inhibitor assays
Human samples and immunohistochemistry (IHC)
Available tissue microarrays (TMA) of primary EwS tumors containing 2 cores of each sample, with a diameter of 1 mm, as well as internal controls were stained for CALCB. Analysis were carried out in approval with the LMU Munich ethics committee.
For IHC, 4-µm sections were cut and antigen retrieval was carried out by heat treatment using target unmasking fluid (PanPath, Budel, Netherlands). Slides were incubated for 60 min at room temperature with a rabbit polyclonal anti-CALCB antibody (bs-0791R, Bioss Antibodies Inc., MA, USA; dilution 1:120). Then slides were incubated with a secondary anti-rabbit IgG antibody (Vectastain ABC-Kit Elite Universal, Vector laboratories, Burlingame, CA, USA) followed by target detection using DAB plus (Agilent Technologies, Santa Clara, CA, USA). Counterstaining was performed with Hematoxylin Gill`s Formula (Vector). Intensity of CALCB staining was scored independently by two researchers in a scale from 0 to 2 (0 = majority of the cells is negative for CALCB staining, 1 = majority of the cells shows moderate CALCB staining, and 2 = majority of the cells shows strong CALCB staining).
CD31 staining and evaluation of microvessel density
For CD31 staining, 4 µm sections of formalin-fixed and paraffin-embedded tumor tissue derived from EwS xenografts in mice were cut, and heat treated using the Target Retrieval Solution (Agilent Technologies). Thereafter, tissue slides were stained with a primary monoclonal rat anti-CD31-antibody (DIA-310, Dianova, Hamburg, Germany; dilution 1:150, 60 min incubation at room temperature). A secondary biotinylated and mouse-absorbed anti-rat-IgG-antibody (BA 4001, Vector; dilution 1:100) was used. After Streptavidin HRP (Novocastra Laboratories, Newcastle upon Tyne, United Kingdom) treatment, DAB plus (Agilent Technologies) was used for target detection. The slides were counterstained with Hematoxylin Gill`s Formula (Vector).
For evaluation of the microvessel density in the CD31 stained slides, the Chalkley-grid method was used 35 . To this end, the number of overlaps of a CD31 positive cell with a dot of the Chalkleygrid in each quarter of the grid in 4 independent regions of the CD31 stained slide was counted, and the mean vessel density of the tumor was calculated.
Mass spectrometry analyses
A673 EwS cells were seeded at a density of 4 ´ 10 6 cells per T150 flask (TPP, Faust) in 20 ml of standard culture medium. After 48 h, the supernatant from the cells was removed, and the cells were washed with PBS (Biochrom) twice. Thereafter, the cells were grown for further 24 h in 20 ml Opti-MEM (Thermo Fisher Scientific) only. Afterwards, the supernatants were collected and immediately frozen at -80°C until the mass spectrometry was performed. For mass spectrometry analysis, samples were lyophilized and resuspended in 50 mM ammonium bicarbonate. 200 µg of protein were reduced and alkylated using 10 mM DTT (Thermo Fisher Scientific) and 100 mM iodoacetamide (Sigma-Aldrich/Merck Millipore), respectively. Next, samples were digested using 20 ng/µl trypsin (NEB) for 18 h at 37°C. Samples were separated in a Nano-HPLC (NanoLC-2D, Eksigent, Sciex, CA, USA) using a C18 column and a gradient composed of solvent A (5% acetonitrile) and solvent B (95% acetonitrile). The program was: 5% acetonitrile for 5 min, 5-100% for 50 min, and 100% for 10 min. Eluted samples were spotted (Eksigent) on a 384-well plate and 1 µl of the matrix α-cyano-4-hydroxycinnamic acid (10 mg/ml in 50% acetonitrile) was added. The mass spectrometry analysis was performed on a MALDI-TOF/TOF 4800 (Sciex) using positive mode. The data were analyzed with the Trans-Proteomic Pipeline (Seattle Proteome Center, WA, USA).
RESULTS
CALCB is an EWSR1-FLI1 target gene highly but heterogeneously expressed in EwS
In the search of potential EWSR1-FLI1 surrogate targets, we analyzed publicly available gene expression microarray data comprising 71 normal tissue types and 50 tumor entities, which identified CALCB as being highly overexpressed in EwS compared to most tumor entities and all normal tissues except for tissue derived from trigeminal ganglia (Figure 1A, B; Supplementary   Fig. S2) . The high expression of CALCB in EwS was validated by immunohistochemical staining of a TMA of primary EwS tumors, of which 44% (39/89) displayed a high and 37% (33/89) an intermediate immunoreactivity score (2 or 1, respectively) for CALCB expression ( Supplementary Fig. S3 ).
This EwS-specific expression pattern suggested a potential regulatory relationship between EwSspecific EWSR1-ETS fusion oncogenes and CALCB. To test this hypothesis, we performed timecourse knockdown experiments of EWSR1-FLI1 in the EwS cell line A673/TR/shEF1, which harbors a dox-inducible shRNA against EWSR1-FLI1 and measured the expression of EWSR1-FLI1 and CALCB at different time points after start of dox-treatment (0-96 h). The results showed that the expression of CALCB is tightly linked to that of EWSR1-FLI1 (Fig. 1C) , which was confirmed in xenografts derived from A673/TR/shEF1 cells in vivo (Fig. 1D) . Conversely, ectopic expression of EWSR1-FLI1 in human embryoid bodies strongly induced CALCB expression ( Fig. 1E) .
To further assess this regulatory relationship, we explored available EWSR1-FLI1 ChIP-seq data from two EwS cell lines (A673 and SK-N-MC) and found strong EWSR1-FLI1 binding at intron 5 of the longest isoform (isoform 3) of the CALCB gene, which mapped to a GGAA-microsatellite that showed epigenetic characteristics of an active enhancer ( Fig. 2A) . Knockdown of EWSR1-FLI1 in both cell lines abolished the EWSR1-FLI1 signal at this GGAA-microsatellite and markedly reduced the signals for acetylated H3K27 (H3K27ac), indicating abrogated enhancer activity upon EWSR1-FLI1 silencing ( Fig. 2A) .
To confirm its EWSR1-FLI1-dependent enhancer activity, we cloned a 359 bp fragment containing this GGAA-microsatellite from two EwS cell lines (TC-71 and MHH-ES1) into the pGL3 luciferase reporter vector and performed reporter assays in A673/TR/shEF1 cells with/without silencing of EWSR1-FLI1. In these assays, we observed strong enhancer activity of the GGAAmicrosatellite, which was significantly diminished upon EWSR1-FLI1 knockdown (Fig. 2B) . In accordance with the higher number of consecutive GGAA-repeats and higher CALCB expression levels in TC-71 EwS cells (12 repeats) as compared to MHH-ES1 EwS cells (9 repeats), we noted a higher enhancer activity of the GGAA-microsatellite derived from TC-71 as compared to the microsatellite derived from MHH-ES1 in luciferase assays (Fig. 2B, Supplementary Fig. S4) .
Collectively, these data provide evidence that CALCB is a direct EWSR1-FLI1 target gene, whose high but heterogeneous expression in EwS is regulated by EWSR1-FLI1 binding to an intronic, polymorphic, and enhancer-like GGAA-microsatellite.
CALCB expression in primary EwS correlates with proliferation signatures
To obtain first clues on the potential functional role of CALCB in EwS, we performed gene set enrichment analysis (GSEA) on CALCB co-expressed genes in a transcriptome dataset of 166 primary EwS 32 . GSEA revealed that CALCB is co-expressed with other EWSR1-FLI1 target genes (ZHANG_TARGETS_OF_EWSR1-FLI1_FUSION) 36 and with gene signatures involved in stemness and proliferation (Fig. 3A, B) .
CALCB signaling in EwS cells contributes to growth of EwS
To test the bioinformatic predictions from our GSEA in primary EwS, we carried out several functional experiments in EwS models. Mass spectrometry analysis showed that CALCB was readily detectable in FCS-free cell culture supernatants conditioned by A673 EwS cells, whereas it was not detectable in FCS-free cell culture medium not conditioned by EwS cells (Supplementary Table 2 ), suggesting that CALCB is indeed secreted by EwS cells. Notably, in accordance with the low expression levels of CALCA in primary EwS cells (Supplementary Fig.   S1 ), CALCA was not detectable in cell culture supernatants of EwS cells ( Supplementary   Table 2 ).
To investigate the functional role of CALCB in EwS, we performed RNA interference experiments in two EwS cell lines (RDES and A673), which showed relatively high or moderate CALCB expression levels as compared to 20 other EwS cell lines (Supplementary Fig. S4) . While the short-term knockdown of CALCB for 3 days had no effect on cellular proliferation ( Supplementary Fig. S5) , its long-term knockdown for 6-9 days significantly reduced proliferation and clonogenic growth in vitro (Fig. 4A, B) . As no differences in the relative number of dead cells was detectable by Trypan-blue labeled cell counting, the reduced proliferation appeared to be not mediated by an increase in cell death (Fig. 4A) .
Interestingly, knockdown of RAMP1 -the crucial component of the CALCB receptor complexphenocopied the effect of CALCB knockdown in clonogenic growth assays (Fig. 4B) as well as in 3D sphere formation assays (Fig. 4C) .
We next investigated whether knockdown of either gene could alter growth of xenografted EwS cells in vivo. To this end, we injected A673 cells, harboring a dox-inducible shRNA against either CALCB or RAMP1, subcutaneously in NSG mice. When tumors were palpable, we induced the knockdown of the respective gene by addition of dox to the drinking water. In both settings, knockdown of the corresponding gene significantly delayed tumor growth, which led to a delayed achievement of a mean tumor diameter of 15 mm, that was defined as termination criteria before, and therefore allowed a prolonged survival of the animals (Fig. 5A, B) . However, dox-treatment of mice carrying tumors with dox-inducible expression of a non-targeting control shRNA did not alter tumor growth compared to mice not receiving dox (data not shown), as also described previously for other xenografted EwS cell lines 31 . Although CALCB and RAMP1 were knocked down to low levels as confirmed by qRT-PCR of tumor tissue ( Fig. 5A, B) , the growth-inhibiting effect was more pronounced in the group of the RAMP1 knockdown.
Taken together, these data suggest that CALCB is a secreted peptide in EwS and that the CALCB/RAMP1-axis promotes growth of EwS cells.
Pharmacological inhibition of the CALCB/RAMP1-axis decreases growth of EwS cells
To test whether the CALCB/RAMP1-axis could also be exploited therapeutically in EwS, we treated EwS cells with the small molecule CGRP-receptor inhibitor MK-3207 for 3 days and quantified cell viability with a Resazurin-assay. For these assays, we used dox-inducible CALCB or RAMP1 knockdown EwS cells and applied increasing doses of MK-3207. We observed a dosedependent reduction of cell viability (Fig. 6A) , which could be partially abrogated by knockdown of RAMP1 -the central component of the inhibitor's target structure (Fig. 6B) . These data suggest that albeit relatively high doses of MK-3207 were applied to reduce viability of EwS cells, its effect was specific for the CALCB/RAMP1-axis. To validate these findings, we performed colony-and sphere-formation assays under MK-3207 treatment and replicated these experiments with another, well known small molecule CGRP inhibitor (Olcegepant, BIBN-4096) (Fig. 6C, D) . In both assays and for both inhibitors we noted a significant reduction of 2D colony-formation and 3D sphere-formation capacity of EwS.
Together, these data provide further evidence for a functional role of the CALCB/RAMP1-axis in growth of EwS, which could potentially be exploited therapeutically.
DISCUSSION
Albeit EwS is a disease, which is genetically well characterized, standard therapy still comprises only unspecific cytotoxic approaches. As it is not possible to directly target the underlying cause of the diseases, an abnormal transcription factor, EWSR1-ETS, which is formed by translocation, current strategies to find new and more specific treatment options is to investigate target genes of EWSR1-ETS and determine their potential as possible new therapy targets. To this end we investigated the potential of the CALCB/RAMP1-axis as new target for treatment of EwS and explored its functional role in EwS cells by combining a series of in situ, in vitro, and in vivo experiments. We found that CALCB is a secreted peptide that shows a highly specific expression pattern among malignant and normal tissues ( Fig. 1A, B, Supplementary Fig. S2) . The high expression of CALCB in EwS is likely driven by EWSR1-FLI1 binding to a GGAA-microsatellite at the CALCB locus. Since this GGAA-microsatellite is transformed into a de novo enhancer upon EWSR1-FLI1 binding but doesn't show enhancer activity in the absence of EWSR1-FLI1, we speculate that different mechanisms may operate in other tissue types such as trigeminal ganglia to upregulate CALCB expression, which remain to be elucidated.
In our long-term knockdown experiments, we observed that silencing of CALCB or RAMP1 reduced growth of EwS cells in vitro and in vivo. To the best of our knowledge this is the first report of a functional role of CALCB in growth of cancer cells to date. However, we noted a weaker effect of the CALCB knockdown as compared to that of RAMP1 on tumor growth in in vivo experiments, which may be caused by residual CALCB expression in the EwS cells (around 5% remaining expression), or alternatively by circulating murine Calcb, which might have compensated at least in part for the loss of human CALCB.
In our drug-response assays we found that inhibition of CGRP-receptors with two different small molecules had a similar anti-proliferative effect on EwS cells to that of the CALCB or RAMP1 knockdown. CGRP-receptor inhibitors already showed high efficacy in the treatment of migraine, which is presumably caused via CALCA-or CALCB-mediated vasodilatation in the vicinity of the trigeminal ganglia -the only normal tissue type with physiologically high CALCB expression levels found in our analyses ( Fig. 1A, Supplementary Fig. S2 ). We speculate that repurposing and further optimization of such 'migraine-drugs' could perhaps offer novel therapeutic options for EwS patients in the future. As we did not observe differences in density of tumor-associated blood vessels quantified by staining for murine CD31 in immunohistochemistry of our xenograft experiments ( Supplementary Fig. S6) , we assume that the growth-promoting effect of the CALCB/RAMP1-axis is conferred via different mechanisms than one would expect from the vasodilatory effect of CALCB known from the literature 37 .
Collectively, we identified CALCB as a highly specifically expressed EWSR1-FLI1 target gene encoding a secreted peptide that promotes growth of EwS cells and show that targeting the CALCB/RAMP1-axis in EwS may offer a new therapeutic approach. Future studies will have to dissect the precise downstream signaling and how the CALCB/RAMP1-axis promotes proliferation of EwS cells, to further explore its therapeutic potential. . D) Analysis of CALCB expression in xenografts derived from A673/TR/shEF1 cells with/without dox-treatment for 96 h in vivo. Gene expression levels were determined by Affymetrix Clariom D microarrays as previously described 29 . Expression levels are shown in log2-scale; horizontal bars indicate mean expression level (n = 3); unpaired two-tailed student's t-test. E) Analysis of CALCB expression in a published dataset (GSE64686) 38 with ectopic EWSR1-FLI1 expression in human embryoid bodies. Data were generated on Affymetrix HG-U133Plus2.0 microarrays and normalized simultaneously by RMA and brainarray CDF (ENTREZg; v21). Horizontal bars indicated mean expression levels; unpaired two-tailed student's t-test. n.s. P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001 
FIGURES
Figure 4: Knockdown of CALCB or RAMP1 inhibits proliferation of EwS cells in vitro.
A) Analysis of cell proliferation and cell death of A673 and RDES EwS cells with/without siRNA-or shRNAmediated knockdown of CALCB. Left panel A673 and RDES: Given is the mean of relative cell count compared to Co (Control) either received according doses of a non-targeting siControl or did not receive dox in assays with dox-inducible shRNAs (n = 3-5). SEM and unpaired two-tailed student's t-test of relative total cell count. Right panel A673 and RDES: Knockdown of CALCB was verified by qRT-PCR. Given is the mean gene expression and SEM; unpaired two-tailed student's t-test. B) Colony-forming assays of A673 and RDES EwS cells with/without siRNA-or dox-inducible shRNAmediated knockdown of CALCB or RAMP1. Mean colony number and SEM normalized to control, which either received according doses of a non-targeting siControl or did not receive dox in assays with dox-inducible shRNAs (n = 3-6). Unpaired two-tailed student's t-test. Representative images of each condition are shown. C) Sphere formation assays of A673 and RDES EwS cells with/without dox-inducible shRNA-mediated knockdown of CALCB and RAMP1. Sphere index was calculated by addition of diameter of all existing spheres in one well divided by diameter of spheres in the control well. Mean and SEM (n = 3-6); unpaired two-tailed student's t-test. n.s. P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001 
